Welcome to our dedicated page for Prophase Labs SEC filings (Ticker: PRPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Investors investigating ProPhase Labs鈥� blend of cutting-edge diagnostics and consumer health products usually start with one question: where in the filings can I find what matters? Whether you鈥檙e tracking COVID-19 test volume, genomics R&D spend or contract-manufacturing margins, our page maps every disclosure so you never hunt through hundreds of pages again.
Use the navigation pane to jump straight to the ProPhase Labs quarterly earnings report 10-Q filing for segment revenue detail, open the ProPhase Labs annual report 10-K simplified for long-term strategy, or scan the latest ProPhase Labs 8-K material events explained for sudden lab expansions. Each document arrives within seconds of hitting EDGAR, and our AI produces concise bullet-point summaries鈥�understanding ProPhase Labs SEC documents with AI truly means saving hours.
Need real-time ownership data? Our alert feed captures ProPhase Labs insider trading Form 4 transactions and flags patterns in ProPhase Labs executive stock transactions Form 4. Curious about compensation? The ProPhase Labs proxy statement executive compensation tab clarifies salary, bonuses and equity grants. For event-driven traders, every headline comes with a one-click ProPhase Labs earnings report filing analysis that highlights diagnostics revenue swings, consumer product sell-through, and manufacturing capacity metrics.
From ProPhase Labs Form 4 insider transactions real-time alerts to AI-tagged risk factors, Stock Titan delivers comprehensive coverage of all SEC forms鈥�10-K, 10-Q, 8-K, 4, S-3 and more鈥攑lus plain-language context. Explore the filings today and move from data to decision without wading through technical jargon.
ProPhase Labs, Inc. reported net revenues of $1.25 million for the three months ended June 30, 2025, down from $1.50 million a year earlier, and $2.68 million for the six months versus $3.86 million a year prior. Gross profit improved to $0.73 million for the quarter from a loss the prior year, reflecting lower cost of goods sold.
The company had $169 thousand in cash and $42.04 million in total assets at June 30, 2025, versus $678 thousand and $63.20 million at year-end 2024. Loss from continuing operations after income taxes was $4.47 million for the quarter and $9.15 million for the six months. The six-month results include an $8.75 million gain on disposal of discontinued operations (PMI). Stockholders' equity was $11.44 million and shares outstanding were 41,541,205 as of August 11, 2025.
Material developments disclosed include the sale of PMI, completion of a BE-Smart validation study with >95% technical success, termination and settlement of New York leases with related asset write-offs and a $1.4 million lease termination loss, equity financing through a Keystone ELOC raising approximately $3.6 million net, and new short-term loan financings including two $625,000 notes issued June 22, 2025 with attached warrants.
ProPhase Labs (PRPH) furnished a press release announcing its financial results for the second quarter ended June 30, 2025 and scheduled a conference call on August 13, 2025 at 2:00 p.m. Eastern Time to discuss those results and corporate developments. The filing explicitly states the press release and related information are being furnished and shall not be deemed "filed" under the Exchange Act or incorporated by reference, and it attaches the press release as Exhibit 99.1 plus a Cover Page Interactive Data File (Inline XBRL) as Exhibit 104. The report also contains forward-looking language addressing the company鈥檚 ability to regain Nasdaq listing compliance or obtain additional time from Nasdaq.
ProPhase Labs, Inc. is soliciting proxies for a Special Meeting of stockholders to vote on six proposals at a meeting on August 29, 2025, including amendments to equity plans, a major increase in authorized common stock, a shareholder repurchase program, approval of a recent private placement, and a bylaw amendment to add the company address. The Board recommends that stockholders vote FOR Proposals 1 through 6.
Key figures disclosed include 41,541,205 shares outstanding as of the record date, a proposal to increase the company鈥檚 authorized common shares from 50,000,000 to 1,000,000,000 to enable a stated crypto treasury strategy, an increase of 3,000,000 shares for the employee equity plan and 500,000 shares for the directors鈥� plan, a non-binding share repurchase program authorizing up to $15 million in buybacks, and shareholder approval sought for issuance of up to 226,310,704 shares (and/or convertible/exercisable securities) in connection with a private placement entered into on July 22, 2025 that may result in issuance exceeding 20% of outstanding shares. The proxy discloses governance features for the proposed plans, including no discounted options, no repricing without shareholder approval, independent committee administration, no evergreen provision, and clawback provisions for awards.
FAQ
What is the current stock price of Prophase Labs (PRPH)?
What is the market cap of Prophase Labs (PRPH)?
